Gallery
- Karnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)Wedding pics: Mouni Roy marries Suraj Nambiar in South Indian ceremony73rd Republic Day Parade 2022 - In Pictures
Lionel Messi has not yet thought about retirement and says age will not be a determining f
- Indian Wells: Alcaraz, Swiatek win titles
- African footballer chased and thrashed away in Kerala; reports
- Hockey India announce core probable group for men's national camp in Bhubaneswar
- Interim Budget: Large number of institutions of higher learning set up, highest ever medal tally in games reflects high confidence level, says FM
- Jyoti Chhatri eyes spot in India's squad for Hockey Olympic Qualifiers
Novel way for weight loss in patients with obesity, diabetes Last Updated : 14 Jan 2021 01:09:02 PM IST Researchers have found that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and Type-2 diabetes.
Bimagrumab is an antibody that blocks activ in type II receptors and stimulates skeletal muscle growth."These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits," said researcher Steve Heymsfield from Pennington Biomedical Research Center, in the US.For the study, published in the JAMA Network Open journal, a total of 75 patients with Type-2 diabetes, body mass index between 28 and 40 and glycated hemoglobin A1c levels between 6.5 percent and 10 per cent were selected for the phase 2 randomized clinical trial.APatients were injected with either Bimagrumab or a placebo (a dextrose solution) every 4 weeks for 48 weeks. Both groups received diet and exercise counselling.At the end of the 48-week study, researchers found a nearly 21 per cent decrease in body fat in the Bimagrumab group compared to 0.5 percent in the placebo group.The results also revealed the Bimagrumab group gained 3.6 percent of lean mass compared with a loss of 0.8 per cent in the placebo group.The combined loss in total body fat and gain in lean mass led to a net 6.5 per cent reduction in body weight in patients receiving Bimagrumab compared with 0.8 per cent weight loss in their counterparts receiving the placebo.IANS New York For Latest Updates Please-
Join us on
Follow us on
172.31.16.186